AU6825198A - Crystalline hydrated sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidin-3-ylidene methyl)-1h-indole-2-carboxylic acid - Google Patents

Crystalline hydrated sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidin-3-ylidene methyl)-1h-indole-2-carboxylic acid

Info

Publication number
AU6825198A
AU6825198A AU68251/98A AU6825198A AU6825198A AU 6825198 A AU6825198 A AU 6825198A AU 68251/98 A AU68251/98 A AU 68251/98A AU 6825198 A AU6825198 A AU 6825198A AU 6825198 A AU6825198 A AU 6825198A
Authority
AU
Australia
Prior art keywords
compound
crystalline hydrated
sodium salt
hydrated form
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU68251/98A
Other languages
English (en)
Inventor
Zadeo Cimarosti
Paolo Maragni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline SpA
Original Assignee
Glaxo Wellcome SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome SpA filed Critical Glaxo Wellcome SpA
Publication of AU6825198A publication Critical patent/AU6825198A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
AU68251/98A 1997-03-05 1998-03-03 Crystalline hydrated sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidin-3-ylidene methyl)-1h-indole-2-carboxylic acid Abandoned AU6825198A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9704498 1997-03-05
GBGB9704498.6A GB9704498D0 (en) 1997-03-05 1997-03-05 Chemical compound
PCT/EP1998/001146 WO1998039327A1 (en) 1997-03-05 1998-03-03 Crystalline hydrated sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidin-3-ylidene methyl)-1h-indole-2-carboxylic acid

Publications (1)

Publication Number Publication Date
AU6825198A true AU6825198A (en) 1998-09-22

Family

ID=10808697

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68251/98A Abandoned AU6825198A (en) 1997-03-05 1998-03-03 Crystalline hydrated sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidin-3-ylidene methyl)-1h-indole-2-carboxylic acid

Country Status (29)

Country Link
EP (1) EP0966463A1 (xx)
JP (1) JP2001513796A (xx)
KR (1) KR20000075907A (xx)
CN (1) CN1249750A (xx)
AP (1) AP9901637A0 (xx)
AR (1) AR011178A1 (xx)
AU (1) AU6825198A (xx)
BG (1) BG103779A (xx)
BR (1) BR9808305A (xx)
CA (1) CA2282851A1 (xx)
CO (1) CO4940415A1 (xx)
EA (1) EA199900710A1 (xx)
EE (1) EE9900387A (xx)
GB (1) GB9704498D0 (xx)
HR (1) HRP980114A2 (xx)
HU (1) HUP0002109A2 (xx)
ID (1) ID24207A (xx)
IL (1) IL131489A0 (xx)
IS (1) IS5166A (xx)
NO (1) NO994303L (xx)
NZ (1) NZ337315A (xx)
OA (1) OA11154A (xx)
PE (1) PE51399A1 (xx)
PL (1) PL335652A1 (xx)
SK (1) SK119699A3 (xx)
TR (1) TR199902117T2 (xx)
WO (1) WO1998039327A1 (xx)
YU (1) YU43499A (xx)
ZA (1) ZA981791B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704499D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Method of manufacture
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
RU2020100230A (ru) 2017-06-12 2021-07-13 Глитек Ллс. Лечение депрессии антагонистами nmda и антагонистами d2/5-ht2a или селективными антагонистами 5-нт2a

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds

Also Published As

Publication number Publication date
PE51399A1 (es) 1999-06-07
IL131489A0 (en) 2001-01-28
NO994303L (no) 1999-11-03
EA199900710A1 (ru) 2000-04-24
BR9808305A (pt) 2000-05-16
EE9900387A (et) 2000-04-17
ID24207A (id) 2000-07-13
HUP0002109A2 (hu) 2001-04-28
SK119699A3 (en) 2000-05-16
IS5166A (is) 1999-08-27
PL335652A1 (en) 2000-05-08
TR199902117T2 (xx) 2000-03-21
OA11154A (en) 2003-04-16
CN1249750A (zh) 2000-04-05
NZ337315A (en) 2001-02-23
BG103779A (en) 2000-06-30
HRP980114A2 (en) 1998-12-31
JP2001513796A (ja) 2001-09-04
KR20000075907A (ko) 2000-12-26
EP0966463A1 (en) 1999-12-29
NO994303D0 (no) 1999-09-03
GB9704498D0 (en) 1997-04-23
CO4940415A1 (es) 2000-07-24
AP9901637A0 (en) 1999-09-30
ZA981791B (en) 1999-09-03
CA2282851A1 (en) 1998-09-11
WO1998039327A1 (en) 1998-09-11
AR011178A1 (es) 2000-08-02
YU43499A (sh) 2000-12-28

Similar Documents

Publication Publication Date Title
AP480A (en) 3-Substituted indole 2-carboxylic acid derivatives.
CA2189053A1 (en) Condensed heterocyclic compounds, their production and use as gnrh antagonists
EP0699186A1 (en) Indole derivatives as antagonists of excitatory amino acids
JPH09503770A (ja) Nmdaアンタゴニストとしてのインドール誘導体
WO2013004190A1 (zh) 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途
AU6825198A (en) Crystalline hydrated sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidin-3-ylidene methyl)-1h-indole-2-carboxylic acid
AU731394B2 (en) Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist
TWI399374B (zh) 新穎晶體形式及製備方法以及其醫藥組合物
CA2393303C (en) Meglumine salt of a specific quinolinecarboxylic acid compound
CZ314799A3 (cs) Krystalická hydratovaná sodná sůl kyseliny (E)-4,6-dichlor-3-(2-oxo-l-fenylpyrrolidin-3- ylidenmethyl)-lH-indol-2-karboxylové
KR20030069228A (ko) 나트륨-수소 교환물질 1형 억제제의 에탄올레이트

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted